It’s taken years of clinical trials, hundreds of millions in annual losses and a roller-coaster market ride toward federal approval.
Now Nerlynx, a new breast cancer drug developed by Puma Biotechnology Inc. of West Los Angeles, has hit pharmacy shelves.
“I’m excited,” said Alan H. Auerbach, Puma’s founder and chief executive. “For every 100 drugs that people bring in for human testing, you’re lucky if one of those goes to market. The production is already being done. It’s stacked on pharmacy shelves. It’s now available.”
The U.S. Food and Drug Administration flipped a green light July 17 for Puma’s single product, also known as neratinib. The once-a-day pill is used to treat certain types of breast cancer after surgery and works by slowing or halting the growth of cancer cells.
The FDA approval was a win for Puma, but also for the greater L.A. biotech community. The region’s biotech industry lags behind hubs in San Diego and San Francisco despite L.A. area’s size and wealth of world-class research institutions such as USC, UCLA and Caltech.
Puma’s ability to develop and market its new cancer drug could help move the region’s biotech industry forward, industry insiders said.
“Bringing that drug to market in such a short period of time is impressive, and good for Los Angeles,” said Ahmed A. Enany, chief executive of Southern California Biomedical Council. “We need success stories like this to show the way for emerging companies to bring their product to market.”
Puma estimates that roughly 36,000 women in the United States with early stage breast cancer qualify for its Nerlynx drug. Clinical trials indicated that it cut the risk of disease recurrence or death by 34 percent. Nerlynx’s downside is frequent or severe diarrhea for a couple of days in its first month of use.
Analysts said the drug – which goes for around $1,800 for 30 pills – could be a boon for Puma. Boston-based investment bank Leerink Partners projects $215 million in 2018 sales with peak sales at $1.3 billion a year. It could generate an additional $350 million in annual sales in Europe if approved by regulators there.
The company’s stock closed Wednesday at $82.55 on Nasdaq, up 162 percent in 2017. That’s shy of Puma’s 12-month trailing high of $97.60 on July 28, but almost triple the stock’s $29 closing price May 8. The company’s market cap is approximately $3 billion.
Puma reported this month a second-quarter loss of $77.8 million, or $2.10 a share. Its yearly loss through the end of June equaled $150.7 million. Combined net losses for 2015 and 2016 amounted to an additional $515 million.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Puma Bio Shares Soar After Tripling Q4 Earnings From Cancer Drug Sales
- Puma Biotechnology Stock Tumbles After Thumbs Down by Euro Drug Regulators
- Puma Breast Cancer Drug Shows Success in Trial
- Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China
- Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug
- Puma Faces $1.3B Lawsuit
- Puma Biotechnology Added to Nasdaq Biotech Index
- Puma Leaps to SE Asia with Licensing Deal